雲頂新耀-B(01952.HK)股價急漲21%至半年高跑贏同業 中金指公司預計Nefecon有望下半年國內獲批上市
雲頂新耀-B(01952.HK)四連跌守穩10天線(18.83元),今天重拾升勢,股價午後高見23.7元創半年高,現報22.95元,急漲21%,成交增至835萬股,創近半個月高。
日前,中金髮布雲頂新耀更新報告稱,公司預計Nefecon有望於下半年在國內獲批上市。該行指出,Nefecon是全球首款獲批用於IgA腎病的創新藥物,在國內已獲得突破性療法認定和優先審評,監於經臨牀驗證的有效性和安全性,以及國內慢性病患者對於創新藥物使用意願積極,認爲Nefecon是在IgA腎病領域具備放量潛力的產品。
其他生物科技企業股(俗稱「B仔股」)方面,東曜藥業-B(01875.HK)最高見2.64元,現報2.5元,回升5.9%。半新股3D MEDICINES-B(01244.HK)續升4.3%報41.6元。貝康醫療-B(02170.HK)、康諾亞-B(02162.HK)、科濟藥業-B(02171.HK)、開拓藥業-B(09939.HK)、鷹瞳科技-B(02251.HK)、諾誠健華-B(09969.HK)及和鉑醫藥-B(2142.HK)升近2%-4.5%,後者升幅最大,最高見3.52元,現報3.5元,續升4.5%。
然而,聖諾醫藥-B(02257.HK)七連跌,現報53.9元,續跌3.3%;康方生物-B(09926.HK)高見49元(受制上週所創52周高位49.4元),掉頭低見45.85元,現報46.2元,倒跌逾3%。三葉草生物-B(02197.HK)、歌禮制藥-B(01672.HK)及騰盛博藥-B(02137.HK)也反覆跌逾1%-2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.